Adam K. Simpson has sold ICVX and made no open-market buys since Aug 2022

Adam K. Simpson is a life sciences entrepreneur and corporate insider who served as President, Chief Executive Officer, and Director of Icosavax, Inc. (Nasdaq: ICVX), where he led the company from its founding through its initial public offering and subsequent acquisition by AstraZeneca.( At Icosavax, he built a team that in‑licensed and advanced a virus‑like particle vaccine platform, moving multiple respiratory disease vaccine candidates into the clinic, including an RSV/hMPV combination vaccine that reached Phase 3 readiness.( As CEO, Simpson oversaw significant partnering and acquisition transactions and held primary executive responsibility for the company’s strategic direction and shareholder value creation.(

Simpson’s career spans more than two decades of building and exiting emerging biopharmaceutical companies. Before Icosavax, he was CEO and board member of PvP Biologics, leading development of an oral enzyme therapy for celiac disease and steering the company from inception through its acquisition by Takeda.( He previously served as President and COO of Cypher Genomics, a genome interpretation firm sold to Human Longevity, Inc.; co‑founder and Chief Business Officer of Meritage Pharma, which was sold to Shire and contributed to the first FDA‑approved oral treatment for eosinophilic esophagitis; and General Counsel at Verus Pharmaceuticals, where he led its sale to AstraZeneca and Shionogi.( Simpson began his career as an attorney at Latham & Watkins and holds a B.S. in biochemistry from the University of California, San Diego and a J.D. from the University of Minnesota Law School.( Beyond his role at Icosavax, he has been a co‑founder, executive, or board member of at least eleven life sciences companies that have either gone public or been acquired, and currently serves as a Venture Partner at Frazier Life Sciences and Executive Board Chair at Callio Therapeutics.(

Written by Perplexity from public sources.